USP Standards For Biological Drugs Would Restrict Innovation, US FDA Says
Executive Summary
Top officials at the US FDA explain why the agency opposes USP monographs for biological products as a Senate committee proposes to disallow them and the USP launches an advertising campaign in their favor.